3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase NA
2
Phase 3
1
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
21
Parkinson Disease 4, Autosomal Dominant Lewy Body
15
Carcinoma, Renal Cell
7
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Squamous Cell Carcinoma of Head and Neck
2
Melanoma
2
von Hippel-Lindau Disease
1
Thyroid Neoplasms
1
Recurrence
1
Neoplasms
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Differentiated Thyroid Cancer (DTC)
1
Colorectal Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Advanced Malignancies
1
Advanced Endometrial Cancer
1
Interventions
Dexamethasone
28
Rituximab
16
pomalidomide
13
Gemcitabine
12
Lenalidomide
11
Cisplatin
11
Bortezomib
11
Paclitaxel
10
Cyclophosphamide
8
Carboplatin
8
carfilzomib
7
selinexor
5
daratumumab
5
Drug Therapy
5
Doxorubicin
5
Cytarabine
5
ibrutinib
4
Vincristine
4
Temozolomide
4
Prednisone
4
Docetaxel
4
Calcium Dobesilate
4
Bevacizumab
4
Aspirin
4
tisagenlecleucel
3
Cetuximab
3
Bendamustine Hydrochloride
3
venetoclax
2
ofatumumab
2
galiximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Recurrence
×
lenvatinib
×
Clear all
NCT05910970
2024-01-23
PREVENT-2
Guangxi Medical University
Phase 3
Unknown
200 enrolled